Vogenx Starts Phase 2b Trial of Mizagliflozin for Post — Bariatric Hypoglycemia

Vogenx today initiated EMERGE, a Phase 2b trial of mizagliflozin for post-bariatric hypoglycemia, which has no FDA-approved treatments. The randomized, placebo-controlled study will enroll approximately 36 adults at about 10 U.S. sites. Participants will receive mizagliflozin or placebo for 28 days to assess safety and reductions in hypoglycemic episodes. Earlier clinical studies showed fewer serious hypoglycemic events; EMERGE will test those findings in a larger, parallel-group setting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vogenx Inc. published the original content used to generate this news brief via (Ref. ID: 202610151635ACCESSWRNAPR_____1237295) on October 15, 2026, and is solely responsible for the information contained therein. (C)